Drug Profile
NCX 470
Alternative Names: Bimatoprost-NO; NCX-470; nitric oxide (NO)-donating bimatoprost prostaglandin analog; NO-bimatoprost; OT-301Latest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator NicOx
- Developer NicOx; Ocumension Therapeutics
- Class Amides; Antiglaucomas; Benzene derivatives; Cycloparaffins; Esters; Lipids; Nitro compounds; Prostaglandins; Small molecules
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Ocular hypertension; Open-angle glaucoma
Most Recent Events
- 20 Mar 2024 Updated data from the phase III Mont Blanc trial in Glaucoma presented in the American Journal of Ophthalmology
- 13 Mar 2024 Nicox announces intention to submit NDA to US FDA for Open-angle glaucoma and Occular hypertension by the end of 2024
- 05 Mar 2024 Efficacy data from the phase III Mont Blanc trial in Open-angle glaucoma and Ocular hypertension released by NicOx